Blue Earth Diagnostics, a leading provider of PET radiopharmaceuticals, is set to present findings on POSLUMA (flotufolastat F 18) injection at the ASTRO 2023 Annual Meeting. POSLUMA aids in PET scans to detect prostate-specific…
Continue Reading
Prostate Cancer Research (PCR) has received sponsorship to support its first of its kind prostate cancer patient data platform and virtual registry.The project, which is supported by IQVIA and sponsored by Bayer and Advanced…
Continue Reading
MRI scans combined with PSA density in prostate cancer screening, pioneered by a UCL-led study, identified cases missed by PSA tests alone. The REIMAGINE study revealed that 15 participants with significant cancer had ‘low’…
Continue Reading
Paige partners with Ohio State Wexner Medical Center to assess AI’s role in precise prostate cancer diagnosis in community hospitals. The collaboration employs the FDA-approved Paige Prostate Detect AI tool to gauge diagnostic accuracy,…
Continue Reading
By Shania Kennedy
June 22, 2023 – Researchers evaluating an artificial intelligence (AI) model’s ability to estimate prostate cancer extent and define focal treatment margins for tumors demonstrated that the model outperformed conventional methods, according to…
Continue Reading
Blue Earth Diagnostics and PETNET Solutions, a Siemens Healthineers Company, have announced the availability of POSLUMA (Flotufolastat F 18) Injection for PET Imaging of Prostate Cancer in the United States. POSLUMA, an optimized PET…
Continue Reading
News
The American Medical Association’s House of Delegates considers a resolution that would urge doctors to educate patients about the risk of large language models. It also directs AMA to work with the federal government…
Continue Reading
Researchers at Houston Methodist have developed an implant that can provide localized and sustained release of immunotherapies to treat pancreatic cancer. Their device is tiny, at approximately the size of a grain of rice,…
Continue Reading
